Pay in 4 interest-free payments of $7.44 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
STAT: cAMP-PKA-signal transducers and activators of transcription
lowest tolerated dose Phase Step 2 Weeks Weeks 5-8 Cagrilintide Dose 0.5 mg/week Purpose Dose escalation Phase Step 3 Weeks Weeks 9-12 Cagrilintide Dose 1.0 mg/week Purpose GI side effects often peak here Phase Step 4 Weeks Weeks 13-16 Cagrilintide Dose 1.7 mg/week Purpose Approaching maintenance Phase Maintenance Weeks Weeks 17+ Cagrilintide Dose 2.4 mg/week Purpose Target dose used in late-stage study protocols Each step lasts 4 weeks
In strict compliance with regulatory laboratory standards, GHK-Cu is distributed exclusively for laboratory research and in vitro experimentation only
ICH Q3A(R2) describes general impurity categories for chemically synthesized substances, and ICH Q3C(R9) describes the control of residual solvents
US$ 24.86
US$ 20.30
US$ 20.59
US$ 28.11
